**Supplemental Material**

**Prevalence of Mendelian kidney disease among patients with high-risk *APOL1* genotypes undergoing commercial genetic testing in the United States**

Ronaldo da Silva Francisco Jr, PhD1, Sumit Punj, PhD2, Lisa Vincent, PhD2, Nina Sanapareddy, PhD2, Vivek Bhalla, MD3, Glenn M. Chertow MD MPH3, Dianne Keen-Kim, PhD1,2, Vivek Charu, MD, PhD1\*

1. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305
2. Natera, Inc. 201 Industrial Boulevard, San Carlos CA 94070
3. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305

**Supplemental Figure 1:** Comparison of self-reported/designated race/ethnicity with genomic ancestry derived from HGDP and 1KG.

**Supplemental Figure 2:** Population Stratification in 1KGP and HGDP Samples highlighting *APOL1* Allele Carriers.

**Supplemental Table 1:** List of 343 Genes Included in our Study.

**Supplemental Table 2:** Comparative Analysis of Self-Reported/Designated Race/Ethnicity and Genetic Clusters Derived from Principal Component Analysis.

**Supplemental Table 3:** Distribution of Global Ancestry Proportions Across Five Continental Populations in Genetic Clusters from Principal Component Analysis.

**Supplemental Table 4:** Global Ancestry Proportions in Five Continental Populations Based on Self-Reported Race and Ethnicity.

**Supplemental Table 5:** Frequency of molecular diagnosed kidney disease across the 343 genes studied, stratified by *APOL1* Genotype.

**Supplemental Table 6:** Detailed Characteristics of Samples with *APOL1* Risk Alleles

**Supplemental Table 7:** Detailed Characteristics of Samples Selected by Matching Analysis

A screenshot of a computer generated image

Description automatically generated

**Supplemental Figure 1: Comparison of self-reported or designated race/ethnicity with genomic ancestry derived from HGDP and 1KG.** *Left Panel:* Each point represents an individual. Points in transparent colors demonstrate individuals from HGDP and 1KG, and points in darker (opaque) colors demonstrate the self-reported race/ethnicity from individuals from our cohort. PC1 and PC2 represent the first two principal components of ancestry informative markers. The genetic diversity across the samples includes five major continental populations: European, African, Admixed American, Central-South Asian, and East Asian, alongside the self-reported race/ethnicity of participants in our study. There is excellent qualitative overlap between the self-reported race/ethnicity and the expected genetic ancestry. *Right Panel:* UMAP visualization based on the first 10 principal components. The sample coloring corresponds to the participants' self-reported race/ethnicity, providing insights into the clustering patterns relative to self-identified groups.

A screenshot of a graph

Description automatically generated

**Supplemental Figure 2: Population Stratification in 1KGP and HGDP Samples highlighting *APOL1* Allele Carriers.** *Left Panel:* This panel shows the global ancestry structure of individuals with high-risk *APOL1* genotypes, represented by black points, illustrating their distribution across the diverse population groups in 1KGP and HGDP Samples. *Right Panel:* Single risk allele carriers for *APOL1* are represented by black points. It is clear in both panels that individuals with high-risk *APOL1* genotypes and single risk allele carriers have recent African ancestry (transparent purple points).

**Supplemental Table 1: List of 343 genes and Mendelian conditions studied.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Gene** | **Disease Name** | **Inheritance** | **Disease Category** | **P/LP variants** |
| *ABCC6* | Pseudoxanthoma elasticum and/or Generalized arterial calcification of infancy | AR | T | Yes |
| *ABCC8* | ABCC8-related disorders | AD;AR | T; G | Yes |
| *ACE* | Renal Tubular Dysgenesis | AR | CS | Yes |
| *ACTB* | ACTB-Related Disorders | AD | CS | No |
| *ACTN4* | Focal Segmental Glomerulosclerosis | AD |  | Yes |
| *ADA2* | Adenosine Deaminase 2 Deficiency (DADA2); Sneddon syndrome | AR | G | Yes |
| *ADAMTS13* | Familial Thrombotic Thrombocytopenic Purpura | AR | CR | Yes |
| *AGPAT2* | Lipodystrophy congenital generalized, type 1 | AR | G | Yes |
| *AGT* | Renal Tubular Dysgenesis | AR | CS | Yes |
| *AGTR1* | Renal Tubular Dysgenesis | AR | CS | Yes |
| *AGXT* | Primary hyperoxaluria type 1 | AR | T | Yes |
| *AHI1* | Joubert Syndrome 3 | AR | CTI | Yes |
| *ALG1* | Congenital Disorder of Glycosylation, Type 1K | AR | G | Yes |
| *ALG8* | Congenital disorder of glycosylation type Ih | AR | CTI | Yes |
| *ALG9* | Polycystic Kidney and Liver Disease (AD); Congenital Disorder of Glycosylation, type 2 (AR); Gillessen Kaesbach Nishimura syndrome (GIKANIS) (AR) | AD;AR | CTI | Yes |
| *ALMS1* | Alstrom syndrome | AR | CTI | Yes |
| *ALPL* | Hypophosphatasia | AD;AR | T | Yes |
| *AMN* | Megaloblastic Anemia 1, Norwegian Type | AR | T | Yes |
| *ANKS6* | Nephronophthisis 16 | AR | CTI | Yes |
| *ANOS1* | Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency | XL | CS | Yes |
| *AP2S1* | Familial Hypocalciuric Hypercalcemia, Type 3 | AD | T | No |
| *APOA1* | Familial Visceral Amyloidosis (AD); Primary Hypoalphalipoproteinemia (AR) | AD;AR | G | Yes |
| *APOC2* | Hyperlipoproteinemia, type Ib | AR | G | Yes |
| *APOPT1* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *APRT* | Adenine Phosphoribosyltransferase Deficiency | AR | T | Yes |
| *AQP2* | Diabetes insipidus, nephrogenic | AD;AR | T | Yes |
| *ARL6* | Bardet-Biedl Syndrome 3 (AR); Retinitis Pigmentosa 55 (AR) | AR | CTI | Yes |
| *ATP6V0A4* | ATP6V0A4-Distal Renal Tubular Acidosis (AR) | AR | T | Yes |
| *ATP6V1B1* | ATP6V1B1-Distal Renal Tubular Acidosis (ATP6V1B1-dRTA) | AR | T | Yes |
| *ATP7B* | Wilson disease | AR | T | Yes |
| *AVP* | Diabetes insipidus, Neurohypophyseal | AD | T | Yes |
| *AVPR2* | Diabetes Insipidus, Nephrogenic | XL | T | Yes |
| *B2M* | Familial Visceral Amyloidosis (AD); Immunodeficiency 43 (AR) | AD;AR | G | Yes |
| *BBS1* | Bardet-Biedl syndrome 1 | AR | CS; CTI | Yes |
| *BBS10* | Bardet-Biedl syndrome 10 | AR | CS; CTI | Yes |
| *BBS12* | Bardet-Biedl syndrome 12 | AR | CS; CTI | Yes |
| *BBS2* | Bardet-Biedl syndrome 2 (AR); Retinitis Pigmentosa 74 (AR) | AR | CS; CTI | Yes |
| *BBS4* | Bardet-Biedl Syndrome 4 | AR | CS; CTI | Yes |
| *BBS5* | Bardet-Biedl Syndrome 5 | AR | CS; CTI | Yes |
| *BBS7* | Bardet-Biedl syndrome 7 | AR | CS; CTI | Yes |
| *BBS9* | Bardet-Biedl syndrome 9 | AR | CTI | Yes |
| *BCS1L* | BCS1L-Related Disorders (AR) | AR | T | Yes |
| *BICC1* | Renal Dysplasia, Cystic | UK | CS; CTI | No |
| *BMP4* | Congenital Anomalies of the Kidney and Urinary Tract; Microphthalmia, syndromic 6 | AD | CS | No |
| *BMPR2* | Pulmonary Hypertension, Familial Primary with or without Hereditary Hemorrhagic Telangiectasia & Pulmonary venoocclusive disease 1 | AD | T | Yes |
| *BRAF* | Noonan Syndrome (AD); Noonan Syndrome with Multiple Lentigines (AD); Cardiofaciocutaneous Syndrome (AD) | AD | CS | No |
| *BSCL2* | BSCL2-related conditions | AD;AR | G | Yes |
| *BSND* | Bartter Syndrome, Type 4a (AR) | AR | T | Yes |
| *C3* | Atypical Hemolytic Uremic Syndrome (AD); C3 Glomerulopathy (AD); C3 deficiency (AR) | AD;AR | CR | Yes |
| *CA2* | Osteopetrosis with Renal Tubular Acidosis | AR | T | Yes |
| *CACNA1H* | Familial Hyperaldosteronism, Type IV (AD) | AD | T | No |
| *CACNA1S* | Hypokalemic Periodic Paralysis Type 1 (AD); Malignant Hyperthermia Susceptibility (AD); Dihydropyridine receptor congenital myopathy (AR) | AD;AR |  | Yes |
| *CASR* | CASR-related conditions | AD;AR | T | Yes |
| *CAV1* | Lipodystrophy, Familial Partial, type 7 (AD); Pulmonary Hypertension, Primary, 3 (AD); Lipodystrophy, Congenital Generalized, Type 3 (AR) | AD;AR | T | Yes |
| *CD151* | Nephropathy with Pretibial Epidermolysis Bullosa and Deafness | AR | G | Yes |
| *CD2AP* | Focal Segmental Glomerulosclerosis 3 (AR); Susceptibility to Focal Segmental Glomerulosclerosis (AD) | AD;AR | G | Yes |
| *CDC73* | CDC73-related Disorders (AD) | AD | T | Yes |
| *CDKN1C* | Beckwith-Wiedemann Syndrome (AD); IMAGe Syndrome (AD) | AD | T | No |
| *CEL* | Maturity-Onset Diabetes of the Young, Type 8 | AD | G | Yes |
| *CEP164* | Senior-Loken Syndrome; Nephronophthisis 15 | AR | CTI | Yes |
| *CEP290* | CEP290-Related Ciliopathies | AR | CTI | Yes |
| *CFH* | Atypical Hemolytic Uremic Syndrome (AD); C3 Glomerulopathy (AD); Complement Factor H Deficiency (AR) | AD;AR | CR | Yes |
| *CFHR5* | Atypical Hemolytic Uremic Syndrome (AD); C3 Glomerulopathy (AD); Complement Factor H Deficiency (AR) | AD;AR | CR | No |
| *CFI* | Atypical Hemolytic Uremic Syndrome (AD); C3 Glomerulopathy (AD); Complement Factor I Deficiency (AR) | AD;AR | CR | Yes |
| *CHD7* | CHARGE syndrome | AD | CS | Yes |
| *CHRM3* | Prune-Belly Syndrome (AR) | AR | CS | No |
| *CHRNA3* | Bladder Dysfunction, Autonomic, with Impaired Pupillary Reflex and Secondary Congenital Anomalies of the Kidney and Urinary Tract | AR | CS | Yes |
| *CISD2* | Wolfram Syndrome 2 | AR | G | No |
| *CLCN2* | Hyperaldosteronism (AD); CLCN2-related leukoencephalopathy (AR) | AD;AR | T | Yes |
| *CLCN5* | Dent disease 1 | XL | T | Yes |
| *CLCNKB* | Bartter Syndrome, Type 3/4B (AR); Gitelman syndrome (AR) | AR | T | Yes |
| *CLDN16* | Hypomagnesemia 3, Renal | AR | T | Yes |
| *CLDN19* | Hypomagnesemia 5, Renal, with Ocular Involvement | AR | T | Yes |
| *CNNM2* | Renal hypomagnesemia (AD/AR) | AD;AR | T | Yes |
| *COL4A1* | COL4A1-Related Disorders | AD | CTI | Yes |
| *COL4A3* | COL4A3-related Alport syndrome | AD;AR | G | Yes |
| *COL4A4* | COL4A4-related Alport syndrome | AD;AR | G | Yes |
| *COL4A5* | Alport syndrome, X-linked | XL | G | Yes |
| *COQ2* | Coenzyme Q10 Deficiency, Primary 1 | AR | G | Yes |
| *COQ6* | Coenzyme Q10 Deficiency, Primary 6 | AR | G | Yes |
| *COX10* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *COX20* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *COX6B1* | Mitochondrial Complex 4 deficiency | AR | T | No |
| *CPLANE1* | Orofaciodigital Syndrome 6 (AR); Joubert syndrome with Oral-Facial-Digital features (AR) | AR | CTI | Yes |
| *CPT2* | Carnitine Palmitoyltransferase II Deficiency (AR) | AR | G; T | Yes |
| *CREBBP* | Rubinstein-Taybi Syndrome, Type 1 (AD); Menke-Hennekam Syndrome (AD) | AD | T | No |
| *CTNS* | Cystinosis | AR | CTI | Yes |
| *CUBN* | Proteinuria, chronic benign; Megaloblastic Anemia 1, FinnishType | AR | G | Yes |
| *CUL3* | Pseudohypoaldosteronism, Type 2E | AD | T | Yes |
| *CYP11A1* | Congenital adrenal insufficiency (CYP11A1-deficiency) | AR | T | Yes |
| *CYP11B1* | Familial hyperaldosteronism type I (AD); Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency (AR) | AD;AR | T | Yes |
| *CYP11B2* | Corticosterone methyloxidase deficiency | AR | T | Yes |
| *CYP17A1* | 17-Alpha-Hydroxylase/7,20-Lyase Deficiency | AR | T | Yes |
| *CYP24A1* | CYP24A1-related hypercalcemia (AR) | AR | T | Yes |
| *CYP27B1* | Vitamin D-Dependent Rickets, Type 1A | AR | T | Yes |
| *CYP2R1* | Rickets due to Defect in Vitamin D 25-hydroxylation | AR | T | Yes |
| *DCDC2* | Nephronophthisis 19 | AR | CTI | Yes |
| *DGKE* | Atypical Hemolytic Uremic Syndrome | AR | G | Yes |
| *DHCR7* | Smith-Lemli-Opitz syndrome | AR | CS | Yes |
| *DLC1* | Nephrotic Syndrome | UK | G | No |
| *DMP1* | Hypophosphatemic Rickets | AR | T | Yes |
| *DNASE1L3* | Systemic Lupus Erythematosus 16 | AR | T | Yes |
| *EBP* | Chondrodysplasia Punctata (XL); MEND syndrome (XL) | XL | T | No |
| *EIF2AK3* | Wolcott-Rallison Syndrome | AR | G | Yes |
| *ELP1* | Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 3 | AR | G | Yes |
| *ENPP1* | Hypophosphatemic Rickets (AR); Generalized arterial calcification of infancy (AR); Cole disease (AD) | AD;AR | T | Yes |
| *EYA1* | Branchiootorenal Spectrum Disorders (AD) | AD | CS | Yes |
| *FAM20A* | Amelogenesis Imperfecta, Type 1G | AR | T | Yes |
| *FAN1* | Interstitial Nephritis, Karyomegalic | AR | CTI | Yes |
| *FANCA* | Fanconi Anemia, Group A (AR) | AR | CS | Yes |
| *FANCB* | Fanconi Anemia, Group B | XL | CS | No |
| *FANCC* | Fanconi Anemia, Group C (AR) | AR | CS | Yes |
| *FANCD2* | Fanconi Anemia, Group D2 | AR | CS | Yes |
| *FANCE* | Fanconi Anemia, Group E | AR | CS | Yes |
| *FANCF* | Fanconi Anemia, Group F | AR | CS | Yes |
| *FANCG* | Fanconi Anemia, Group G | AR | CS | Yes |
| *FANCI* | Fanconi Anemia, Group I | AR | CS | Yes |
| *FANCL* | Fanconi Anemia, Group L | AR | CS | Yes |
| *FASTKD2* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *FGA* | Hereditary Renal Amyloidosis (AD); Congenital Fibrinogen Deficiency (AR) | AD;AR | G | Yes |
| *FGF10* | Lacrimo-auriculo-dento-digital (LADD) Syndrome | AD | CS | No |
| *FGF23* | Hypophosphatemic Rickets (AD); Tumoral Calcinosis, Hyperphosphatemic (AR) | AD;AR | T | Yes |
| *FGFR1* | FGFR1-related conditions | AD | CS | Yes |
| *FGFR2* | FGFR2-related conditions | AD | CS | Yes |
| *FLCN* | Birt-Hogg-Dubé syndrome (AD); Primary Spontaneous Pneumothorax (AD) | AD | CTI | Yes |
| *FN1* | Glomerulopathy With Fibronectin Deposits 2 (AD); Corner Fracture Type Spondylometaphyseal Dysplasia (AD) | AD | G | Yes |
| *FOXC1* | Axenfeld-Rieger Syndrome, Type 3 | AD | CS | Yes |
| *FOXC2* | Lymphedema-Distichiasis Syndrome with Renal Disease and Diabetes Mellitus | AD | G | Yes |
| *FOXI1* | Hereditary Distal Renal Tubular Acidosis (AR) | AR | T | No |
| *FOXP3* | IPEX syndrome (including type 1 diabetes) | XL | G | Yes |
| *FRAS1* | Fraser Syndrome | AR | CS | Yes |
| *FREM1* | FREM1-related conditions | AD;AR | CS | Yes |
| *FREM2* | Fraser Syndrome | AR | CS | Yes |
| *FXYD2* | Hypomagnesemia 2, Renal | AD | T | No |
| *G6PC* | Glycogen storage disease, type 1a | AR | T | Yes |
| *GALNT3* | Hyperphosphatemic Familial Tumoral Calcinosis | AR | T | Yes |
| *GANAB* | Polycystic Kidney and/or Polycystic Liver Disease | AD | CTI | Yes |
| *GATA3* | Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia | AD | CS | Yes |
| *GATM* | Cerebral creatine deficiency syndrome 3 (AR); Fanconi renotubular syndrome 1 (AD) | AD;AR | T | Yes |
| *GCK* | Maturity-onset diabetes of the young, type 2 (AD); Late onset, non insulin dependent diabetes mellitus (AD); Permanent neonatal diabetes mellitus 1 (AR); Familial hyperinsulinemic hypoglycemia 3 (AD) | AD;AR | G | Yes |
| *GCM2* | Familial Isolated Hypoparathyroidism (AD/AR); Familial Isolated Hyperparathyroidism (AD) | AD;AR | T | Yes |
| *GLA* | Fabry disease | XL | G | Yes |
| *GLI3* | GLI3-Related Disorders | AD | CS | Yes |
| *GLIS2* | Nephronophthisis 7 | AR | CTI | No |
| *GLIS3* | Diabetes Mellitus, Neonatal, With Congenital Hypothyroidism | AR | G; CTI | Yes |
| *GNA11* | Autosomal Dominant Hypocalcemia 2 (AD); Hypocalciuric hypercalcemia, type II (AD) | AD | T | No |
| *GNAS* | GNAS-Related Disorders | AD | T | Yes |
| *GPC3* | Simpson-Golabi-Behmel Syndrome, Type 1 | XL | CS | Yes |
| *GRHPR* | Hyperoxaluria, Primary, Type 2 | AR | T | Yes |
| *GRIP1* | Fraser Syndrome | AR | CS | Yes |
| *GSN* | Amyloidosis, Finnish Type | AD | G | Yes |
| *HBB* | Beta-Hemoglobinopathies (AD/AR); Sickle cell disease (AR) | AD;AR | G; T | Yes |
| *HGD* | Alkaptonuria | AR | T | Yes |
| *HNF1A* | HNF1A-MODY (Maturity-Onset Diabetes of the Young) | AD | CTI | Yes |
| *HNF1B* | HNF1B-Related Disorders | AD | CTI; CS | Yes |
| *HNF4A* | Fanconi Renotubular Syndrome 4, with or without Maturity-Onset Diabetes of the Young (MODY), Type 1 (AD); MODY, Type 1 (AD); Congenital Hyperinsulinism (AD); Diabetes Mellitus, Type 2 (AD) | AD | G | Yes |
| *HOGA1* | Primary Hyperoxaluria, Type 3 | AR | T | Yes |
| *HOXA13* | Hand-Foot-Uterus Syndrome | AD | CS | Yes |
| *HPRT1* | HPRT1-Related Disorders (XL) | XL | T | No |
| *HPS1* | Hermansky-Pudlak syndrome 1 | AR | G | Yes |
| *HPSE2* | Urofacial Syndrome (AR) | AR | CS | Yes |
| *HSD11B2* | Apparent Mineralocorticoid Excess | AR | T | Yes |
| *HSD3B2* | Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | AR | T | Yes |
| *IFT122* | Cranioectodermal Dysplasia, Type 1 | AR | CTI | Yes |
| *IFT140* | Retinitis pigmentosa 80; Short-Rib Thoracic Dysplasia 9 with or without Polydactyly | AR | CTI | Yes |
| *IFT172* | Short-Rib Thoracic Dysplasia 10 With Or Without Polydactyly (AR); Bardet-Biedl syndrome 20 (AR); Retinitis Pigmentosa 71 (AR) | AR | CTI | Yes |
| *IFT43* | Cranioectodermal Dysplasia, Type 3 | AR | CTI | Yes |
| *INF2* | Focal Segmental Glomerulosclerosis 5; Charcot-Marie-Tooth Disease E | AD | G | Yes |
| *INS* | Diabetes mellitus, insulin-dependent, 2 (AD); Diabetes mellitus, permanent neonatal 4 (AD/AR); Maturity-onset diabetes of the young, type 10 (AD); Hyperproinsulinemia (AD) | AD;AR | G | Yes |
| *INVS* | Nephronophthisis 2; Senior-Loken syndrome | AR | CTI | Yes |
| *IQCB1* | Senior-Loken Syndrome 5 | AR | CTI | Yes |
| *ITGA3* | Interstitial Lung Disease with Nephrotic Syndrome and Epidermolysis Bullosa | AR | G | Yes |
| *ITGA6* | Junctional Epidermolysis Bullosa- Pyloric Atresia Syndrome | AR | CS | Yes |
| *ITGB4* | Junctional Epidermolysis Bullosa-Pyloric Atresia Syndrome | AD;AR | G | Yes |
| *JAG1* | Alagille Syndrome, Type 1 | AD | CS | Yes |
| *KANSL1* | Koolen-De Vries Syndrome | AD | CS | Yes |
| *KAT6B* | Genitopatellar syndrome; SBBYSS syndrome | AD | CS | No |
| *KCNA1* | Episodic Ataxia Type 1 | AD | T | No |
| *KCNJ1* | Bartter syndrome | AR | T | Yes |
| *KCNJ10* | Seizures, Sensorineural Deafness, Ataxia, Mental Retardation, and Electrolyte Imbalance (SeSAME Syndrome) | AR | T | Yes |
| *KCNJ11* | KCNJ11-Related Diabetes (AD); Familial Hyperinsulinism (AD/AR)0 | AD;AR | G | Yes |
| *KCNJ5* | Familial Hyperaldosteronism Type 3 | AD | T | No |
| *KCNK3* | Pulmonary Hypertension, Primary 4 | AD | T | No |
| *KCTD1* | Scalp-Ear-Nipple Syndrome | AD | CS | No |
| *KLHL3* | Pseudohypoaldosteronism, Type 2D | AD;AR | T | Yes |
| *KRAS* | Cardiofaciocutaneous Syndrome (AD); Noonan Syndrome (AD) | AD | CS | No |
| *LAMB2* | Nephrotic Syndrome, Type 5, with or without Ocular Abnormalities; Pierson Syndrome | AR | G | Yes |
| *LCAT* | Complete LCAT Deficiency (AR); Partial LCAT Deficiency (AR) | AR | G | Yes |
| *LDHA* | Glycogen Storage Disease, Type 11 | AR | T | Yes |
| *LMNA* | LMNA-Related Disorders | AD;AR | G | Yes |
| *LMX1B* | Nail-Patella Syndrome (AD); Focal Segmental Glomerulosclerosis 10 (AD) | AD | G | Yes |
| *LPIN1* | Myoglobinuria, Acute Recurrent | AR | G | Yes |
| *LRP2* | Donnai-Barrow Syndrome | AR | T | Yes |
| *LRP4* | Cenani-Lenz Syndactyly Syndrome | AR | CS | Yes |
| *LRP5* | LRP5-Related Disorders | AD;AR | CTI | Yes |
| *LYZ* | Amyloidosis, Familial Visceral, Renal | AD | G | No |
| *LZTFL1* | Bardet-Biedl Syndrome, Type 17 | AR | CTI | Yes |
| *MAFB* | Multicentric Carpotarsal Osteolysis with or without Nephropathy | AD | G | Yes |
| *MAGI2* | Nephrotic Syndrome 15 | AR | G | Yes |
| *MEFV* | Familial Mediterranean fever | AR | G | Yes |
| *MKKS* | Bardet-Biedl Syndrome, Type 6 (AR); McKusick-Kaufman syndrome (AR) | AR | CTI | Yes |
| *MMACHC* | Methylmalonic aciduria and homocystinuria, cblC type | AR | CR | Yes |
| *MNX1* | Currarino Syndrome | AD | CS | Yes |
| *MOCOS* | Xanthinuria, Type II | AR | T | Yes |
| *MUT* | Methylmalonic Aciduria, Type mut0 (AR) | AR | G; T | Yes |
| *MVK* | Mevalonate Kinase Deficiency | AR | G | Yes |
| *MYCN* | Feingold Syndrome 1 (AD) | AD | CS | No |
| *MYH9* | MYH9-Related Disorders (AD) | AD | G | Yes |
| *MYO1E* | Focal Segmental Glomerulosclerosis, 6 | AR | G | Yes |
| *NEK8* | Nephronophthisis 9; Renal-Hepatic-Pancreatic Dysplasia | AR | CTI | Yes |
| *NEUROD1* | Maturity-Onset Diabetes of the Young 6 | AD | G | Yes |
| *NF1* | Neurofibromatosis, Type 1 | AD | G; T | Yes |
| *NLRP3* | Cryopyrin-Associated Periodic Syndromes (CAPS) (AD) | AD | G | No |
| *NOTCH2* | Acroosteolysis Dominant Type; Alagille syndrome 2; Hajdu- Cheney Syndrome | AD | CS; CTI | Yes |
| *NPHP1* | Nephronophthisis 1, Juvenile; Senior-Loken Syndrome; Joubert Syndrome 4 | AR | CTI | Yes |
| *NPHP3* | NPHP3-related conditions | AR | CTI | Yes |
| *NPHP4* | Nephronophthisis 4; Senior-Loken syndrome 4 | AR | CTI | Yes |
| *NPHS1* | Congenital Nephrotic Syndrome, Finnish Type | AR | G | Yes |
| *NPHS2* | Congenital nephrotic syndrome, type 2 | AR | G | Yes |
| *NR0B1* | Congenital Adrenal Hypoplasia with Hypogonadotropic Hypogonadism | XL | T | Yes |
| *NR3C1* | Glucocorticoid Resistance, Generalized | AD | T | Yes |
| *NR3C2* | Pseudohypoaldosteronism Type I, Autosomal Dominant Hypertension, Early-Onset | AD | T | Yes |
| *NSD1* | Sotos Syndrome | AD | CS | Yes |
| *NSDHL* | CHILD syndrome (XLD); CK syndrome (XLR) | XL | CS | Yes |
| *OCRL* | Dent disease 2; Lowe Syndrome | XL | T | Yes |
| *OFD1* | OFD1-Related Conditions (XL) | XL | CTI | Yes |
| *OPLAH* | 5-Oxoprolinase Deficiency | AR | T | Yes |
| *PAX2* | PAX2-Related Disorders (AD) | AD | CS; G | Yes |
| *PBX1* | Congenital Anomalies of the Kidney and Urinary Tract syndrome with or without Hearing Loss, Abnormal Ears, or Developmental Delay (CAKUTHED) | AD | CS | Yes |
| *PCBD1* | BH4-Deficient Hyperphenylalaninemia D (AR); Juvenile-Onset Diabetes Mellitus (AR) | AR | G; T | Yes |
| *PDSS1* | Coenzyme Q10 Deficiency, Primary, 2 | AR | G | Yes |
| *PDSS2* | Coenzyme Q10 Deficiency, Primary, 3 | AR | G | Yes |
| *PDX1* | PDX1-familial monogenic diabetes, Pancreatic agenesis 1 | AD;AR | G | Yes |
| *PET100* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *PGK1* | Phosphoglycerate kinase 1 deficiency | XL | T | No |
| *PHEX* | Hypophosphatemic Rickets | XL | T | Yes |
| *PKD1* | Polycystic Kidney Disease 1 | AD | CTI | Yes |
| *PKD2* | Polycystic Kidney Disease 2 | AD | CTI | Yes |
| *PKHD1* | Autosomal Recessive Polycystic Kidney Disease | AR | CTI | Yes |
| *PLCE1* | Nephrotic Syndrome, Type 3 | AR | G | Yes |
| *PLG* | Congenital Plasminogen Deficiency (AR) | AR | CR | Yes |
| *PMM2* | Congenital Disorder of Glycosylation, Type 1A; Hyperinsulinemic Hypoglycemia and Polycystic Kidney Disease | AR | G | Yes |
| *PPP3CA* | Arthrogryposis, Cleft Palate, Craniosynostosis, and Impaired Intellectual Development | AD | T | No |
| *PRKCSH* | Polycystic Liver Disease 1 | AD | CTI | Yes |
| *PRODH* | Hyperprolinemia, Type 1 | AR | CS; G; T | Yes |
| *PROKR2* | Hypogonadotropic hypogonadism 3 with or without anosmia | AD;AR | CS | Yes |
| *PRPS1* | Phosphoribosylpyrophosphate synthetase superactivity | XL | T | No |
| *PTH1R* | Metaphyseal Chondrodysplasia, Murk Jansen Type (AD); Failure of tooth eruption, primary (AD); Chondrodysplasia, Blomstrand type (AR); Eiken syndrome (AR) | AD;AR | CTI | Yes |
| *PTPN11* | Noonan Syndrome (AD); Noonan Syndrome with Multiple Lentigines (AD) | AD | CS | Yes |
| *PTPRO* | Nephrotic Syndrome, Type 6 | AR | G | Yes |
| *RAD51C* | Fanconi Anemia, Group O | AR | CS | Yes |
| *REN* | Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-REN) (AD); Renal Tubular Dysgenesis (REN-dRTD) (AR) | AD;AR | CTI | Yes |
| *RET* | Multiple endocrine neoplasia 2A/2B; Familial medullary thyroid carcinoma | AD | CS | Yes |
| *RMND1* | Combined Oxidative Phosphorylation Deficiency 11 | AR | CS | Yes |
| *ROBO2* | Congenital Anomalies of the Kidney and Urinary Tract | AD | CS | No |
| *ROR2* | Brachydactyly, type B1 (AD), Robinow Syndrome (AR) | AR | T | Yes |
| *RPGRIP1L* | Ciliopathies, RPGRIP1L-Related | AR | CTI | Yes |
| *RPL11* | Diamond-Blackfan Anemia 7 | AD | CS | Yes |
| *RPL35A* | Diamond-Blackfan Anemia 5 | AD | CS | No |
| *RPL5* | Diamond-Blackfan Anemia 6 | AD | CS | No |
| *RPS10* | Diamond-Blackfan Anemia 9 | AD | CS | No |
| *RPS17* | Diamond-Blackfan Anemia 4 | AD | CS | No |
| *RPS19* | Diamond-Blackfan Anemia 1 | AD | CS | No |
| *RPS24* | Diamond-Blackfan Anemia 3 | AD | CS | No |
| *RPS26* | Diamond-Blackfan Anemia 10 | AD | CS | No |
| *RPS7* | Diamond-Blackfan Anemia 8 | AD | CS | No |
| *RRM2B* | RRM2B Mitochondrial DNA Maintenance Defects (RRM2B-MDMDs) (AD/AR) | AD;AR | T | Yes |
| *SALL1* | Townes-Brocks syndrome 1 | AD | CS | Yes |
| *SALL4* | SALL4-Related Disorders (AD) | AD | CS | No |
| *SARS2* | Hyperuricemia, Pulmonary Hypertension, Renal Failure, And Alkalosis Syndrome (HUPRA Syndrome) (AR) | AR | T | Yes |
| *SCARB2* | Action Myoclonus-Renal Failure (AMRF) Syndrome | AR | G | Yes |
| *SCN4A* | SCN4A-Related Disorders | AD;AR | T | Yes |
| *SCNN1A* | Pseudohypoaldosteronism, Type 1 | AR | T | Yes |
| *SCNN1B* | Liddle Syndrome 1 (AD); Pseudohypoaldosteronism, Type 1 (AR) | AD;AR | T | Yes |
| *SCNN1G* | Liddle Syndrome 2 (AD); Pseudohypoaldosteronism, type 1 (AR) | AD;AR | T | Yes |
| *SCO1* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *SDCCAG8* | Senior Loken Syndrome, Type 7; Bardet-Biedl Syndrome 16 | AR | CTI | Yes |
| *SEC63* | Polycystic Liver Disease 2 | AD | T | Yes |
| *SEMA3E* | CHARGE syndrome | UK | CS | No |
| *SI* | Sucrase-Isomaltase Deficiency | AR | T | Yes |
| *SIX1* | Branchiootorenal Spectrum Disorders (AD) | AD | CS | No |
| *SIX5* | Branchiootorenal Spectrum Disorders (AD) | AD | CS | No |
| *SLC12A1* | Bartter syndrome | AR | T | Yes |
| *SLC12A3* | Gitelman syndrome | AR | T | Yes |
| *SLC16A12* | Juvenile cataract with microcornea | AD | T | No |
| *SLC22A12* | Hypouricemia, Renal 1 | AR | T | Yes |
| *SLC26A1* | Nephrolithiasis, Calcium Oxalate | AR | T | No |
| *SLC2A2* | Fanconi-Bickel Syndrome | AR | T | Yes |
| *SLC2A9* | Renal Hypouricemia 2 | AD;AR | T | Yes |
| *SLC34A1* | Hypophosphatemic Nephrolithiasis/Osteoporosis 1 (AD) & Infantile Hypercalcemia 2 (AR) | AD;AR | T | Yes |
| *SLC34A3* | Hypophosphatemic Rickets with Hypercalciuria | AR | T | Yes |
| *SLC37A4* | Glycogen Storage Disease, Type 1B/1C (AR) | AR | G; T | Yes |
| *SLC3A1* | Cystinuria​​​​ | AD;AR | T | Yes |
| *SLC4A1* | SLC4A1-associated Distal Renal Tubular Acidosis (AD/AR); Ovalocytosis, SA Type (AD); Cryohydrocytosis (AD); Spherocytosis, Type 4 (AD) | AD;AR | T | Yes |
| *SLC4A4* | Renal Tubular Acidosis, Proximal, with Ocular Abnormalities | AR | T | Yes |
| *SLC5A1* | Glucose-Galactose Malabsorption | AR | T | Yes |
| *SLC5A2* | Renal Glucosuria | AD;AR | T | Yes |
| *SLC6A19* | Hyperglycinuria (AD); Hartnup Disorder (AR); Iminoglycinuria (Complex) | AD;AR | T | Yes |
| *SLC7A7* | Lysinuric protein intolerance | AR | T | Yes |
| *SLC7A9* | Cystinuria​​​​ | AD;AR | T | Yes |
| *SLX4* | Fanconi Anemia, Group P | AR | CS | Yes |
| *SMAD9* | Pulmonary Hypertension, Primary 2 | AD | T | Yes |
| *SMARCAL1* | Schimke immunoosseous dysplasia | AR | G | Yes |
| *SMC1A* | Cornelia de Lange Syndrome (XL); Developmental and Epileptic Encephalopathy 85, with or without Midline Brain Defects (DEE85) | XL | CS | Yes |
| *SOX17* | Vesicoureteral Reflux 3 | AD | CS | Yes |
| *SOX18* | SOX18-Related Disorders (AD/AR) | AD;AR | G; ? | No |
| *SRCAP* | Floating-Harbor Syndrome | AD | CS; T | Yes |
| *STAR* | Lipoid Adrenal Hyperplasia | AR | CS | Yes |
| *STX16* | Pseudohypoaldosteronism | AD | T | No |
| *TACO1* | Mitochondrial Complex 4 deficiency | AR | T | Yes |
| *TFAP2A* | Branchiooculofacial Syndrome | AD | CS | No |
| *THBD* | Atypical Hemolytic Uremic Syndrome | AD | CR | Yes |
| *TMEM67* | TMEM67-related conditions | AR | CTI | Yes |
| *TNS2* | Nephrotic Syndrome | UK | G | No |
| *TP53RK* | Galloway-Mowat Syndrome | AR | G | No |
| *TP63* | P63-Related Conditions | AD | CS | Yes |
| *TRIM32* | Limb-girdle muscular dystrophy, type 2H (AR) | AR | CTI | Yes |
| *TRPC6* | Focal Segmental Glomerulosclerosis 2 | AD | G | Yes |
| *TRPM6* | Hypomagnesemia 1, Intestinal | AR | T | Yes |
| *TSC1* | Tuberous sclerosis | AD | CTI | Yes |
| *TSC2* | Tuberous sclerosis | AD | CTI | Yes |
| *TTC21B* | Nephronophthisis 12; Short-rib thoracic dysplasia 4 with or without polydactyly | AR | CTI; G | Yes |
| *TTC8* | Bardet-Biedl Syndrome 8 | AR | CTI | Yes |
| *TXNL4A* | Burn-McKeown syndrome | AR | CS | Yes |
| *UMOD* | Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-UMOD) (AD) | AD | CTI | Yes |
| *UPK3A* | Renal Hypodysplasia | UK | CS | No |
| *UQCC2* | Mitochondrial Complex 3 Deficiency, Nuclear Type 7 | AR | T | Yes |
| *VDR* | Vitamin D-dependent Rickets, Type 2A | AR | T | Yes |
| *VHL* | Von Hippel-Lindau Syndrome (AD); Familial Erythrocytosis 2 (AR) | AD | CTI | Yes |
| *WAS* | Wiskott-Aldrich Syndrome (XL); X-Linked Thrombocytopenia (XL); X-Linked Severe Congenital Neutropenia (XL) | XL | G | No |
| *WDPCP* | Bardet-Biedl Syndrome 15 | AR | CTI | Yes |
| *WDR19* | WDR19-related conditions (see note below) | AR | CTI | Yes |
| *WDR72* | Amelogenesis Imperfecta with or without Distal Renal Tubular Acidosis - WDR72 | AR | T | Yes |
| *WDR73* | Galloway-Mowat Syndrome | AR | G | Yes |
| *WFS1* | Wolfram Syndrome Spectrum Disorder (AD/AR) | AD;AR | CS; T | Yes |
| *WNK1* | Pseudohypoaldosteronism, Type 2C (AD); Autosomal recessive Neuropathy, hereditary sensory and autonomic, type II (AR) | AD;AR | T | Yes |
| *WNK4* | Pseudohypoaldosteronism, Type 2B | AD | T | Yes |
| *WNT4* | Mullerian Aplasia and Hyperandrogenism | AD | CS | No |
| *WNT5A* | Robinow Syndrome 1 | AD | CS | No |
| *WT1* | WT1-Related Disorders | AD | CS; G | Yes |
| *XDH* | Xanthinuria, Type I | AR | T | Yes |
| *XPNPEP3* | Nephronophthisis-Like Nephropathy 1 | AR | CTI | Yes |
| *XRCC4* | Short Stature, Microcephaly, and Endocrine Dysfunction | AR | CS | Yes |

Disease Category Abbreviation

*CTI Cystic & Tubulointerstitial Disorders*

*G Glomerular Disorders*

*T Tubulopathy and Tubular Disorders*

*CS CAKUT & Structural Disorders*

*CR Complement-related Kidney Disorders*

**Supplemental Table 2: Comparative analysis of self-reported or designated race/ethnicity and genetic clusters derived from principal component analysis.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Self-reported race/ethnicity** | **No. of Unique Samples** | | **Genetic Cluster** |  |  |  |  |  |
|  |  | **Admixed American** | | **African** | **Central-South Asian** | **East Asian** | **European** | **Unclustered Samples\*** |
| African American | 2893 | 15 | | 2718 | 2 | 0 | 26 | 132 |
| Caucasian | 5563 | 138 | | 51 | 9 | 20 | 5110 | 235 |
| East Asian | 213 | 0 | | 1 | 12 | 192 | 2 | 6 |
| Hispanic | 1912 | 1540 | | 115 | 0 | 17 | 179 | 61 |
| Mediterranean | 70 | 0 | | 1 | 7 | 1 | 58 | 3 |
| Multiples | 241 | 31 | | 53 | 8 | 23 | 116 | 10 |
| Other | 445 | 41 | | 54 | 49 | 107 | 180 | 14 |
| South-East Asian | 302 | 1 | | 0 | 135 | 147 | 8 | 11 |
| Unknown | 3542 | 547 | | 685 | 146 | 262 | 1779 | 123 |

\*No. of Samples excluded during PCA filtering steps due to missing the minimum number of single-nucleotide variants after quality control.

**Supplemental Table 3: Distribution of global ancestry proportions across five continental populations in genetic clusters from principal component analysis.** Numbers displayed are median proportions and interquartile ranges.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Genetic Cluster** | **N** | **Global Ancestry Proportions** | | | | |
|  |  | **African** | **European** | **Admixed\_American** | **East Asian** | **Central-South Asian** |
| Admixed American | 2313 | 0.05 [0.02-0.09] | 0.44 [0.34-0.54] | 0.37 [0.26-0.48] | 0.06 [0.01-0.11] | 0 [0-0.08] |
| African | 3678 | 0.7 [0.63-0.76] | 0.22 [0.15-0.29] | 0.01 [0-0.06] | 0.01 [0-0.05] | 0 [0-0.04] |
| Central-South Asian | 368 | 0 [0-0.02] | 0.33 [0.26-0.43] | 0.03 [0-0.08] | 0.3 [0.22-0.36] | 0.29 [0.24-0.34] |
| East Asian | 769 | 0 [0-0] | 0.04 [0-0.09] | 0.06 [0-0.13] | 0.87 [0.78-0.93] | 0 [0-0] |
| European | 7458 | 0 [0-0.02] | 0.82 [0.75-0.88] | 0.01 [0-0.06] | 0.01 [0-0.07] | 0.1 [0.02-0.15] |

**Supplemental Table 4: Global ancestry proportions in five continental populations based on self-reported or designated race/ethnicity.** Numbers displayed are median proportions and interquartile ranges.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Self-reported race /ethnicity** | **N** | **Genetic cluster** | | | | |
|  |  | **African** | **European** | **Admixed American** | **East Asian** | **Central-South Asian** |
| African American | 2761 | 0.71 [0.64-0.77] | 0.21 [0.15-0.28] | 0.02 [0-0.05] | 0.01 [0-0.05] | 0 [0-0.04] |
| Caucasian | 5328 | 0 [0-0.01] | 0.83 [0.76-0.89] | 0.01 [0-0.06] | 0.01 [0-0.07] | 0.09 [0.01-0.14] |
| East Asian | 207 | 0 [0-0] | 0.01 [0-0.06] | 0.06 [0.01-0.12] | 0.89 [0.81-0.94] | 0 [0-0] |
| Hispanic | 1851 | 0.06 [0.02-0.12] | 0.45 [0.34-0.55] | 0.35 [0.19-0.47] | 0.05 [0-0.11] | 0 [0-0.08] |
| Mediterranean | 67 | 0.02 [0-0.06] | 0.68 [0.59-0.76] | 0.02 [0-0.08] | 0.03 [0-0.1] | 0.15 [0.09-0.23] |
| Multiples | 231 | 0.03 [0.01-0.22] | 0.58 [0.32-0.77] | 0.03 [0-0.13] | 0.05 [0-0.11] | 0.05 [0-0.13] |
| Other | 431 | 0.01 [0-0.06] | 0.46 [0.14-0.71] | 0.04 [0-0.11] | 0.11 [0.02-0.44] | 0.05 [0-0.18] |
| South-East Asian | 291 | 0 [0-0.01] | 0.2 [0.04-0.35] | 0.04 [0-0.11] | 0.51 [0.3-0.87] | 0.05 [0-0.28] |
| Unknown | 3419 | 0.01 [0-0.11] | 0.65 [0.28-0.83] | 0.03 [0-0.12] | 0.03 [0-0.1] | 0.04 [0-0.13] |

**Supplemental Table 5: Frequency of molecular diagnosed kidney disease across the 343 genes studied, stratified by APOL1 Genotype.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Inheritance** | **Total** | **Percentage (%)** | **High Risk APOL1 Genotype** | | **Single Risk Allele Carriers** | | **G0/G0** |  |
|  |  |  |  | **N** | **%** | **N** | **%** | **N** | **%** |
| *PKD1* | AD | 769 | 5.07 | 18 | 1.74 | 61 | 3.62 | 690 | 5.54 |
| *COL4A4* | AD;AR | 362 | 2.38 | 23 | 2.22 | 35 | 2.07 | 304 | 2.44 |
| *COL4A3* | AD;AR | 282 | 1.86 | 6 | 0.58 | 13 | 0.77 | 263 | 2.11 |
| *COL4A5* | XL | 268 | 1.77 | 9 | 0.87 | 17 | 1.01 | 242 | 1.94 |
| *PKD2* | AD | 268 | 1.77 | 3 | 0.29 | 26 | 1.54 | 239 | 1.92 |
| *HNF1B* | AD | 133 | 0.88 | 5 | 0.48 | 10 | 0.59 | 118 | 0.95 |
| *SLC12A3* | AR | 79 | 0.52 | 0 | 0 | 5 | 0.3 | 74 | 0.59 |
| *UMOD* | AD | 77 | 0.51 | 0 | 0 | 4 | 0.24 | 73 | 0.59 |
| *GLA* | XL | 50 | 0.33 | 0 | 0 | 5 | 0.3 | 45 | 0.36 |
| *SLC7A9* | AD;AR | 46 | 0.3 | 0 | 0 | 2 | 0.12 | 44 | 0.35 |
| *NPHP1* | AR | 36 | 0.24 | 0 | 0 | 1 | 0.06 | 35 | 0.28 |
| *CLCN5* | XL | 35 | 0.23 | 0 | 0 | 4 | 0.24 | 31 | 0.25 |
| *ABCC8* | AD;AR | 31 | 0.2 | 1 | 0.1 | 2 | 0.12 | 28 | 0.22 |
| *CFI* | AD;AR | 29 | 0.19 | 0 | 0 | 4 | 0.24 | 25 | 0.2 |
| *COL4A1* | AD | 29 | 0.19 | 2 | 0.19 | 0 | 0 | 27 | 0.22 |
| *HBB* | AD;AR | 28 | 0.18 | 8 | 0.77 | 4 | 0.24 | 16 | 0.13 |
| *PAX2* | AD | 28 | 0.18 | 0 | 0 | 3 | 0.18 | 25 | 0.2 |
| *NPHS2* | AR | 26 | 0.17 | 0 | 0 | 0 | 0 | 26 | 0.21 |
| *TSC2* | AD | 22 | 0.14 | 0 | 0 | 0 | 0 | 22 | 0.18 |
| *CASR* | AD;AR | 19 | 0.13 | 3 | 0.29 | 1 | 0.06 | 15 | 0.12 |
| *SLC2A9* | AD;AR | 19 | 0.13 | 0 | 0 | 2 | 0.12 | 17 | 0.14 |
| *SLC3A1* | AD;AR | 19 | 0.13 | 1 | 0.1 | 0 | 0 | 18 | 0.14 |
| *INF2* | AD | 18 | 0.12 | 0 | 0 | 0 | 0 | 18 | 0.14 |
| *CFH* | AD;AR | 17 | 0.11 | 1 | 0.1 | 1 | 0.06 | 15 | 0.12 |
| *GANAB* | AD | 16 | 0.11 | 0 | 0 | 0 | 0 | 16 | 0.13 |
| *HNF1A* | AD | 17 | 0.11 | 0 | 0 | 0 | 0 | 17 | 0.14 |
| *PRKCSH* | AD | 15 | 0.1 | 1 | 0.1 | 1 | 0.06 | 13 | 0.1 |
| *SLC4A1* | AD;AR | 15 | 0.1 | 0 | 0 | 2 | 0.12 | 13 | 0.1 |
| *TRPC6* | AD | 15 | 0.1 | 1 | 0.1 | 1 | 0.06 | 13 | 0.1 |
| *PKHD1* | AR | 14 | 0.09 | 0 | 0 | 1 | 0.06 | 13 | 0.1 |
| *CLCNKB* | AR | 12 | 0.08 | 1 | 0.1 | 0 | 0 | 11 | 0.09 |
| *FLCN* | AD | 12 | 0.08 | 1 | 0.1 | 1 | 0.06 | 10 | 0.08 |
| *WT1* | AD | 12 | 0.08 | 1 | 0.1 | 1 | 0.06 | 10 | 0.08 |
| *ALG9* | AD;AR | 10 | 0.07 | 0 | 0 | 0 | 0 | 10 | 0.08 |
| *ALPL* | AD;AR | 10 | 0.07 | 1 | 0.1 | 0 | 0 | 9 | 0.07 |
| *NR3C2* | AD | 11 | 0.07 | 0 | 0 | 1 | 0.06 | 10 | 0.08 |
| *OFD1* | XL | 10 | 0.07 | 0 | 0 | 1 | 0.06 | 9 | 0.07 |
| *PROKR2* | AD;AR | 10 | 0.07 | 1 | 0.1 | 1 | 0.06 | 8 | 0.06 |
| *SEC63* | AD | 10 | 0.07 | 1 | 0.1 | 0 | 0 | 9 | 0.07 |
| *SMAD9* | AD | 11 | 0.07 | 2 | 0.19 | 2 | 0.12 | 7 | 0.06 |
| *WFS1* | AD;AR | 10 | 0.07 | 0 | 0 | 2 | 0.12 | 8 | 0.06 |
| *AVPR2* | XL | 9 | 0.06 | 0 | 0 | 1 | 0.06 | 8 | 0.06 |
| *CEL* | AD | 9 | 0.06 | 1 | 0.1 | 2 | 0.12 | 6 | 0.05 |
| *CUBN* | AR | 9 | 0.06 | 0 | 0 | 1 | 0.06 | 8 | 0.06 |
| *GATA3* | AD | 9 | 0.06 | 0 | 0 | 1 | 0.06 | 8 | 0.06 |
| *RET* | AD | 9 | 0.06 | 0 | 0 | 1 | 0.06 | 8 | 0.06 |
| *SCNN1B* | AD;AR | 9 | 0.06 | 0 | 0 | 5 | 0.3 | 4 | 0.03 |
| *CD2AP* | AD;AR | 7 | 0.05 | 1 | 0.1 | 0 | 0 | 6 | 0.05 |
| *CTNS* | AR | 7 | 0.05 | 0 | 0 | 0 | 0 | 7 | 0.06 |
| *FGA* | AD;AR | 8 | 0.05 | 0 | 0 | 0 | 0 | 8 | 0.06 |
| *HNF4A* | AD | 7 | 0.05 | 0 | 0 | 1 | 0.06 | 6 | 0.05 |
| *LMX1B* | AD | 7 | 0.05 | 0 | 0 | 1 | 0.06 | 6 | 0.05 |
| *NF1* | AD | 7 | 0.05 | 1 | 0.1 | 1 | 0.06 | 5 | 0.04 |
| *OCRL* | XL | 8 | 0.05 | 0 | 0 | 4 | 0.24 | 4 | 0.03 |
| *PBX1* | AD | 7 | 0.05 | 0 | 0 | 0 | 0 | 7 | 0.06 |
| *SALL1* | AD | 8 | 0.05 | 0 | 0 | 0 | 0 | 8 | 0.06 |
| *SLC5A2* | AD;AR | 7 | 0.05 | 1 | 0.1 | 0 | 0 | 6 | 0.05 |
| *CYP24A1* | AR | 6 | 0.04 | 0 | 0 | 0 | 0 | 6 | 0.05 |
| *JAG1* | AD | 6 | 0.04 | 0 | 0 | 0 | 0 | 6 | 0.05 |
| *NOTCH2* | AD | 6 | 0.04 | 0 | 0 | 4 | 0.24 | 2 | 0.02 |
| *NSD1* | AD | 6 | 0.04 | 0 | 0 | 0 | 0 | 6 | 0.05 |
| *PHEX* | XL | 6 | 0.04 | 0 | 0 | 2 | 0.12 | 4 | 0.03 |
| *AGXT* | AR | 5 | 0.03 | 0 | 0 | 0 | 0 | 5 | 0.04 |
| *ANOS1* | XL | 4 | 0.03 | 2 | 0.19 | 0 | 0 | 2 | 0.02 |
| *APOA1* | AD;AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *APRT* | AR | 4 | 0.03 | 0 | 0 | 1 | 0.06 | 3 | 0.02 |
| *ATP6V0A4* | AR | 5 | 0.03 | 0 | 0 | 0 | 0 | 5 | 0.04 |
| *ATP7B* | AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *C3* | AD;AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *EYA1* | AD | 5 | 0.03 | 1 | 0.1 | 1 | 0.06 | 3 | 0.02 |
| *GCK* | AD;AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *KLHL3* | AD;AR | 5 | 0.03 | 0 | 0 | 0 | 0 | 5 | 0.04 |
| *LMNA* | AD;AR | 5 | 0.03 | 0 | 0 | 0 | 0 | 5 | 0.04 |
| *MEFV* | AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *NPHP4* | AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *PTPN11* | AD | 4 | 0.03 | 1 | 0.1 | 0 | 0 | 3 | 0.02 |
| *SLC12A1* | AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *SLC34A1* | AD;AR | 4 | 0.03 | 0 | 0 | 0 | 0 | 4 | 0.03 |
| *VHL* | AD | 4 | 0.03 | 1 | 0.1 | 0 | 0 | 3 | 0.02 |
| *CDC73* | AD | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *CNNM2* | AD;AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *FAN1* | AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *FGFR1* | AD | 3 | 0.02 | 1 | 0.1 | 0 | 0 | 2 | 0.02 |
| *FOXC1* | AD | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *GNAS* | AD | 3 | 0.02 | 1 | 0.1 | 0 | 0 | 2 | 0.02 |
| *GRHPR* | AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *INS* | AD;AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *MYH9* | AD | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *NPHS1* | AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *NR3C1* | AD | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *PDX1* | AD;AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *REN* | AD;AR | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *SCN4A* | AD;AR | 3 | 0.02 | 0 | 0 | 1 | 0.06 | 2 | 0.02 |
| *TSC1* | AD | 3 | 0.02 | 0 | 0 | 0 | 0 | 3 | 0.02 |
| *ABCC6* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *ACTN4* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *ADA2* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *AQP2* | AD;AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *ATP6V1B1* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *AVP* | AD | 1 | 0.01 | 0 | 0 | 1 | 0.06 | 0 | 0 |
| *BBS1* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *BBS10* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *BBS2* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *BBS9* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *BMPR2* | AD | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *BSCL2* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CA2* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CACNA1S* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CAV1* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CEP290* | AR | 2 | 0.01 | 0 | 0 | 1 | 0.06 | 1 | 0.01 |
| *CHD7* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CLCN2* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CLDN19* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CPLANE1* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *CUL3* | AD | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *CYP11B1* | AD;AR | 1 | 0.01 | 0 | 0 | 1 | 0.06 | 0 | 0 |
| *CYP27B1* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *FAM20A* | AR | 2 | 0.01 | 0 | 0 | 1 | 0.06 | 1 | 0.01 |
| *FANCC* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *FGF23* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *FGFR2* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *FN1* | AD | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *FOXC2* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *FOXP3* | XL | 2 | 0.01 | 0 | 0 | 1 | 0.06 | 1 | 0.01 |
| *G6PC* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *GALNT3* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *GLI3* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *GPC3* | XL | 1 | 0.01 | 0 | 0 | 1 | 0.06 | 0 | 0 |
| *GSN* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *HOGA1* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *HOXA13* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *HSD11B2* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *IFT140* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *IQCB1* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *KANSL1* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *KCNJ1* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *KCNJ11* | AD;AR | 1 | 0.01 | 1 | 0.1 | 0 | 0 | 0 | 0 |
| *LRP5* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *MAFB* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *MMACHC* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *MNX1* | AD | 1 | 0.01 | 0 | 0 | 1 | 0.06 | 0 | 0 |
| *NEUROD1* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *NPHP3* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *NR0B1* | XL | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *NSDHL* | XL | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *PMM2* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *PTH1R* | AD;AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *RMND1* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *RPL11* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *RRM2B* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *SCARB2* | AR | 2 | 0.01 | 0 | 0 | 1 | 0.06 | 1 | 0.01 |
| *SCNN1A* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *SCNN1G* | AD;AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *SDCCAG8* | AR | 2 | 0.01 | 0 | 0 | 0 | 0 | 2 | 0.02 |
| *SMC1A* | XL | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *SOX17* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *SRCAP* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *THBD* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *TMEM67* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *TP63* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *TRPM6* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *TTC21B* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *TXNL4A* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *WDR19* | AR | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |
| *WNK4* | AD | 1 | 0.01 | 0 | 0 | 0 | 0 | 1 | 0.01 |

**Supplemental Table 6: Detailed Characteristics of Samples with *APOL1* Risk Alleles**

|  |  |  |
| --- | --- | --- |
| Characteristic | High Risk Genotype | Single Risk Allele Carriers |
| Self-reported race & ethnicity |  |  |
| African American | 802 | 1137 |
| Caucasian | 6 | 36 |
| East Asian | 0 | 0 |
| Hispanic | 36 | 127 |
| Mediterranean | 0 | 0 |
| Multiples | 13 | 23 |
| Other | 17 | 23 |
| South-East Asian | 0 | 0 |
| Unknown | 161 | 341 |
| Genetic cluster |  |  |
| Admixed American | 27 | 141 |
| African | 944 | 1453 |
| Central-South Asian | 0 | 2 |
| East Asian | 0 | 1 |
| European | 4 | 37 |
| Ancestry Proportions |  |  |
| Admixed American | 0.02 [0-0.06] | 0.02 [0-0.07] |
| African | 0.71 [0.65-0.77] | 0.69 [0.59-0.75] |
| Central-South Asian | 0 [0-0.04] | 0 [0-0.04] |
| East Asian | 0.01 [0-0.05] | 0.01 [0-0.06] |
| European | 0.21 [0.15-0.28] | 0.23 [0.16-0.32] |

**Supplemental Table 7: Detailed Characteristics of Samples Selected by Matching Analysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Categories** | **All Patients** | **High Risk Genotype** | **Single Risk Genotype** | **G0/G0** |
| No. of Samples | 2890 | 975 | 952 | 963 |
| Gender & Age |  |  |  |  |
| Female | 1335 (46.2) | 446 (45.7) | 433 (45.5) | 456 (47.4) |
| Male | 1555 (53.8) | 529 (54.3) | 519 (54.5) | 507 (52.6) |
| Age yr [IQR] | 46 [31-59] | 45 [32-57] | 46 [32-60] | 47 [28.5-62] |
| Mendelian Disease Status |  |  |  |  |
| Affected | 376 (13) | 92 (9.4) | 128 (13.4) | 156 (16.2) |
| Carrier | 1000 (34.6) | 354 (36.3) | 336 (35.3) | 310 (32.2) |
| Negative | 1514 (52.4) | 529 (54.3) | 488 (51.3) | 497 (51.6) |
| Self-reported race & ethnicity |  |  |  |  |
| African American | 2158 (74.7) | 749 (76.8) | 708 (74.4) | 701 (72.8) |
| Caucasian | 29 (1) | 6 (0.6) | 7 (0.7) | 16 (1.7) |
| Hispanic | 102 (3.5) | 33 (3.4) | 28 (2.9) | 41 (4.3) |
| Multiples | 38 (1.3) | 13 (1.3) | 10 (1.1) | 15 (1.6) |
| Others | 44 (1.5) | 17 (1.7) | 7 (0.7) | 20 (2.1) |
| Unknown | 519 (18) | 157 (16.1) | 192 (20.2) | 170 (17.7) |
| Genomic Ancestry Proportions |  |  |  |  |
| African | 0.71 [0.65-0.77] | 0.71 [0.65-0.77] | 0.72 [0.65-0.77] | 0.71 [0.64-0.77] |
| Admixed American | 0.02 [0-0.06] | 0.02 [0-0.06] | 0.02 [0-0.06] | 0.02 [0-0.06] |
| Central-South Asian | 0 [0-0.04] | 0 [0-0.04] | 0 [0-0.04] | 0 [0-0.04] |
| East Asian | 0.01 [0-0.05] | 0.01 [0-0.05] | 0.01 [0-0.05] | 0.01 [0-0.05] |
| European | 0.21 [0.15-0.28] | 0.21 [0.15-0.28] | 0.21 [0.14-0.28] | 0.21 [0.15-0.28] |
| Genetic Cluster |  |  |  |  |
| Admixed American | 73 (2.5) | 27 (2.8) | 26 (2.7) | 20 (2.1) |
| African | 2791 (96.6) | 944 (96.8) | 920 (96.6) | 927 (96.3) |
| Central-South Asian | 1 (0) | 0 (0) | 1 (0.1) | 0 (0) |
| European | 25 (0.9) | 4 (0.4) | 5 (0.5) | 16 (1.7) |
| Chronic kidney disease | 1675 | 547 (32.7) | 561 (33.5) | 567 (33.9) |
| End-stage kidney disease | 473 | 226 (47.8) | 133 (28.1) | 114 (24.1) |
| Unclustered samples | 225 | 68 (30.2) | 77 (34.2) | 80 (35.6) |
| Clinical diagnosis (ICD codes)& |  |  |  |  |
| Proteinuria/nephrotic syndrome | 223 | 74 (33.2) | 77 (34.5) | 72 (32.3) |
| Cystic kidney disease | 168 | 33 (19.6) | 67 (39.9) | 68 (40.5) |
| Others | 148 | 22 (14.9) | 56 (37.8) | 70 (47.3) |
| Hypertension | 107 | 27 (25.2) | 36 (33.6) | 44 (41.1) |
| Kidney transplant | 60 | 26 (43.3) | 17 (28.3) | 17 (28.3) |
| Nephritic syndrome | 59 | 32 (54.2) | 12 (20.3) | 15 (25.4) |
| Hematuria | 58 | 16 (27.6) | 23 (39.7) | 19 (32.8) |
| Kidney stone | 4 | 3 (75) | 0 (0) | 1 (25) |